Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

    ... MDS/CMML (defined as ≥ 10% peripheral blood or marrow blasts and/or IPSS score ≥ 1.5) and relapsed or refractory to ...

    Clinical Trial last updated 06/06/2016 - 10:47am.

  2. MDS is a Complicated Group of Disorders

    ... cases MDS progresses from lower- risk to higher-risk as blasts (immature white blood cells) increase in the bone marrow .  When the percentage of blasts reaches 20% or more, the patient is diagnosed as having acute ...

    Page last updated 06/27/2012 - 1:51pm.

  3. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... Disease status: remission or <10% bone marrow blasts Myelodysplasia Acute lymphoblastic leukemia Disease status: ...

    Clinical Trial last updated 06/03/2016 - 2:45pm.

  4. Phase I, Dose Escalation Study of Decitabine

    ... (CR) following allo-HSCT ( bone marrow leukemic blasts less than 5% by morphology ), with high risk features ...

    Clinical Trial last updated 06/06/2016 - 9:44am.

  5. Allo HSCT Using RIC for Hematological Diseases

    ... be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a ... <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy ...

    Clinical Trial last updated 05/02/2016 - 9:29am.

  6. Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

    ... adult patients with pathologically confirmed MDS (< 20% blasts in bone marrow , peripheral blood, or both) by World Health ...

    Clinical Trial last updated 05/03/2016 - 9:46am.

  7. Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

    ... or morphologic complete remission or MDS - Marrow blasts must be > 5% and disease failed at least 1 prior hypomethylating ...

    Clinical Trial last updated 05/02/2016 - 11:06am.

  8. Specialized technique effective in identifying chromosomal abnormalities, improving prognosis for MDS

    ... based solely on the percentage of bone marrow blasts , cytogenetics (branch of genetics which studies the ...

    Research Review last updated 05/02/2016 - 9:31am.

  9. Clofarabine in the treatment of myelodysplastic syndromes

    ... DNA synthesis and can reduce the percentage of leukemic blasts in adult patients with MDS and acute myeloid leukemia (AML).  Early ...

    Research Review last updated 05/02/2016 - 9:18am.

  10. Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

    ... confirmed Myelodysplastic Syndrome, or MDS, (< 20% blasts in bone marrow , peripheral blood, or both) by World Health ...

    Clinical Trial last updated 04/29/2016 - 1:36pm.